Rezultati pretrage - Motoya, Satoshi

Disruption of Lymphocyte Function and Signaling in CD45–associated Protein–null Mice od Matsuda, Akio, Motoya, Satoshi, Kimura, Shioko, McInnis, Renee, Maizel, Abby L., Takeda, Akiko

Preuzmi cijeli tekst Preuzmi cijeli tekst

Association between expression of intercellular adhesion molecule‐1 and integration of human T‐cell‐leukemia virus type 1 in adult T‐cell leukemia cells od Motoya, Satoshi, Tsujisaki, Masayuki, Jinnohara, Tsuneharu, Sasaki, Shigeru, Nakano, Tatsumi, Hinoda, Yuji, Imai, Kohzoh

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial an... od Kobayashi, Taku, Suzuki, Yasuo, Motoya, Satoshi, Hirai, Fumihito, Ogata, Haruhiko, Ito, Hiroaki, Sato, Noriko, Ozaki, Kunihiko, Watanabe, Mamoru, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study od Yokoyama, Tadashi, Ohta, Akihiko, Motoya, Satoshi, Takazoe, Masakazu, Yajima, Toshitaka, Date, Masataka, Nii, Masahiro, Nagy, Péter, Suzuki, Yasuo, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenanc... od Hisamatsu, Tadakazu, Kim, Hyo Jong, Motoya, Satoshi, Suzuki, Yasuo, Ohnishi, Yoshifumi, Fujii, Noriyuki, Matsushima, Nobuko, Zheng, Richuan, Marano, Colleen W.

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis od Suzuki, Yasuo, Watanabe, Mamoru, Matsui, Toshiyuki, Motoya, Satoshi, Hisamatsu, Tadakazu, Yuasa, Hirotoshi, Tabira, Junichi, Isogawa, Naoki, Tsuchiwata, Shinichi, Arai, Shoko, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan od Tajiri, Hitoshi, Motoya, Satoshi, Kinjo, Fukunori, Maemoto, Atsuo, Matsumoto, Takayuki, Sato, Noriko, Yamada, Hiroshi, Nagano, Mieko, Susuta, Yutaka, Ozaki, Kunihiko, Kondo, Kazuoki, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan od Tajiri, Hitoshi, Motoya, Satoshi, Kinjo, Fukunori, Maemoto, Atsuo, Matsumoto, Takayuki, Sato, Noriko, Yamada, Hiroshi, Nagano, Mieko, Susuta, Yutaka, Ozaki, Kunihiko, Kondo, Kazuoki, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies od Motoya, Satoshi, Watanabe, Mamoru, Kim, Hyo Jong, Kim, Young Ho, Han, Dong Soo, Yuasa, Hirotoshi, Tabira, Junichi, Isogawa, Naoki, Arai, Shoko, Kawaguchi, Isao, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies od Motoya, Satoshi, Watanabe, Mamoru, Kim, Hyo Jong, Kim, Young Ho, Han, Dong Soo, Yuasa, Hirotoshi, Tabira, Junichi, Isogawa, Naoki, Arai, Shoko, Kawaguchi, Isao, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study od Hibi, Toshifumi, Motoya, Satoshi, Ashida, Toshifumi, Sai, Souken, Sameshima, Yukinori, Nakamura, Shiro, Maemoto, Atsuo, Nii, Masahiro, Sullivan, Barbara A, Gasser Jr, Robert A., Suzuki, Yasuo

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis od Suzuki, Yasuo, Motoya, Satoshi, Hanai, Hiroyuki, Hibi, Toshifumi, Nakamura, Shiro, Lazar, Andreas, Robinson, Anne Martin, Skup, Martha, Mostafa, Nael Mohamed, Huang, Bidan, Thakkar, Roopal, Watanabe, Mamoru

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study od Motoya, Satoshi, Watanabe, Kenji, Ogata, Haruhiko, Kanai, Takanori, Matsui, Toshiyuki, Suzuki, Yasuo, Shikamura, Mitsuhiro, Sugiura, Kenkichi, Oda, Kazunori, Hori, Tetsuharu, Araki, Takahiro, Watanabe, Mamoru, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study od Motoya, Satoshi, Watanabe, Kenji, Ogata, Haruhiko, Kanai, Takanori, Matsui, Toshiyuki, Suzuki, Yasuo, Shikamura, Mitsuhiro, Sugiura, Kenkichi, Oda, Kazunori, Hori, Tetsuharu, Araki, Takahiro, Watanabe, Mamoru, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis od Suzuki, Yasuo, Motoya, Satoshi, Hanai, Hiroyuki, Hibi, Toshifumi, Nakamura, Shiro, Lazar, Andreas, Robinson, Anne Martin, Skup, Martha, Mostafa, Nael Mohamed, Huang, Bidan, Thakkar, Roopal, Watanabe, Mamoru

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses od Watanabe, Kenji, Motoya, Satoshi, Ogata, Haruhiko, Kanai, Takanori, Matsui, Toshiyuki, Suzuki, Yasuo, Shikamura, Mitsuhiro, Sugiura, Kenkichi, Oda, Kazunori, Hori, Tetsuharu, Araki, Takahiro, Watanabe, Mamoru, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis od Suzuki, Yasuo, Motoya, Satoshi, Hanai, Hiroyuki, Matsumoto, Takayuki, Hibi, Toshifumi, Robinson, Anne M., Mostafa, Nael M., Chao, Jingdong, Arora, Vipin, Camez, Anne, Thakkar, Roopal B., Watanabe, Mamoru

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy od Motoya, Satoshi, Watanabe, Mamoru, Wallace, Kori, Lazar, Andreas, Nishimura, Yasuko, Ozawa, Morio, Thakkar, Roopal, Robinson, Anne M., Singh, Ravi Shankar Prasad, Mostafa, Nael M., Suzuki, Yasuo, Hibi, Toshifumi

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Predicting a rapid response to adalimumab treatment and favorable short-term outcomes through the high platelet count in patients with ulcerative colitis: A multicenter retrospecti... od Sakemi, Ryosuke, Miyakawa, Maki, Tanaka, Hiroki, Nasuno, Masanao, Motoya, Satoshi, Tanuma, Tokuma, Ishii, Manabu, Yanagisawa, Hideyuki, Yamashita, Masaki, Toita, Nariaki, Suzuki, Ryo, Kobayashi, Toshihisa, Nojima, Masanori, So, Suketo

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis od Naganuma, Makoto, Watanabe, Kenji, Motoya, Satoshi, Ogata, Haruhiko, Matsui, Toshiyuki, Suzuki, Yasuo, Ursos, Lyann, Sakamoto, Shigeru, Shikamura, Mitsuhiro, Hori, Tetsuharu, Fernandez, Jovelle, Watanabe, Mamoru, Hibi, Toshifumi, Kanai, Takanori

Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst